Evidence map›Paper›PMID 38321271›Full record

ArticleBone marrow transplantation2024

The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.

Masamitsu Yanada, Shingo Yano, Yachiyo Kuwatsuka, Koji Kawamura, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Hashii, Hideki Goto, Koji Kato, Fumihiko Ishimaru and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Masamitsu YanadaNagoya City University East Medical Center, Nagoya, Japan. myanada@med.nagoya-cu.ac.jp.ORCID 0000-0003-1602-9775
Shingo YanoThe Jikei University School of Medicine, Tokyo, Japan.ORCID 0000-0002-5895-5382
Yachiyo KuwatsukaNagoya University Hospital, Nagoya, Japan.
Koji KawamuraTottori University Hospital, Yonago, Japan.
Takahiro FukudaNational Cancer Center Hospital, Tokyo, Japan.
Tatsuo IchinoheResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko HashiiOsaka International Cancer Institute, Osaka, Japan.
Hideki GotoHokkaido University Hospital, Sapporo, Japan.
Koji KatoKyushu University Hospital, Fukuoka, Japan.
Fumihiko IshimaruJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.ORCID 0000-0002-7668-6083
Atsushi SatoMiyagi Children's Hospital, Sendai, Japan.
Makoto OnizukaTokai University School of Medicine, Isehara, Japan.ORCID 0000-0003-3864-0823
Keitaro MatsuoAichi Cancer Center Research Institute, Nagoya, Japan.ORCID 0000-0003-1761-6314
Yuri ItoOsaka Medical and Pharmaceutical University, Osaka, Japan.
Atsumi YanagisawaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Marie OhbikiJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.ORCID 0009-0007-3522-2278
Ken TabuchiJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.ORCID 0000-0003-4404-2870
Junya KandaGraduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6704-3633
Takaaki KonumaThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-1953-8463

Funding

Aichi Cancer Research Foundation (Aichi Cancer Research for the Promotion of Science Foundation) 2023-1-7Japan Agency for Medical Research and Development (AMED) 19ek0510023h0003
6 · The paper itself

Abstract

This study aimed to address the prognostic impact of center experience based on the data of 7821 adults with acute myeloid leukemia who underwent allogeneic hematopoietic cell transplantation (HCT) from 2010 to 2019 in Japan, where medical care was provided within a uniform healthcare system. Center experience was defined based on the number of allogeneic HCTs performed for any indication during the study period, by which centers were divided into low-, intermediate-, and high-volume centers. After adjusting for known confounding factors, the risk of overall mortality was lowest for the high-volume centers and highest for the low-volume centers, with the difference between the center categories attributed primarily to the risk of relapse. Patients transplanted at high-volume centers had higher risks of acute and chronic graft-versus-host diseases but without an increased risk of non-relapse mortality (NRM). These findings reveal the presence of a center effect in allogeneic HCT conducted during the past decade in Japan, highlighting the difference in relapse based on center experience. The weaker effect on NRM compared with that on relapse suggests that the transplantation care quality is becoming equalized across the country.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultHumansPrognosisRecurrenceRetrospective StudiesTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID38321271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.